Our Pipeline
TianTi Biotherapeutics Pipeline
We are developing novel biologics that, by leveraging our unique technologies, will provide new approaches for modulating diseases including muscular dystrophies and cancer.
The LUB-001 target is a novel oncogenic driver, overexpressed on a wide range of tumors, and involved in tumor cell survival, proliferation, and metastasis. Antibodies against this target could bring a new approach for multiple solid tumor treatment.
The LUB-002 is for treatment of genetically and clinically heterogeneous subgroup of congenital muscular dystrophies. TianTi Bio is using a bispecific antibody approach to restore muscle cell function.
The LUB-003 target is overexpressed on a wide range of tumors and is involved in tumor cell survival. Antibodies against this target could bring a new approach for multiple solid tumor treatment.
Chinese